Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis
Background: Central neurocytoma (CN) is a rare tumor accounting for
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-08, Vol.13 (17), p.4308 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 17 |
| container_start_page | 4308 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Samhouri, Laith Meheissen, Mohamed A. M. Ibrahimi, Ahmad K. H. Al-Mousa, Abdelatif Zeineddin, Momen Elkerm, Yasser Hassanein, Zeyad M. A. Ismail, Abdelsalam Attia Elmansy, Hazem Al-Hanaqta, Motasem M. AL-Azzam, Omar A. Elsaid, Amr Abdelaziz Kittel, Christopher Micke, Oliver Stummer, Walter Elsayad, Khaled Eich, Hans Theodor |
| description | Background: Central neurocytoma (CN) is a rare tumor accounting for |
| doi_str_mv | 10.3390/cancers13174308 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8430823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2570620806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-ad54d95d5f7dc8d23f44d98278241ef44b825ea14a9eafe7e5929159f9488ea83</originalsourceid><addsrcrecordid>eNpdkU1PGzEQhq2qqCDg3KslLr0E_Llrc6gURdBGogUheraMd5Y43bVT20uVf1-nQRXFh_GM5plX84HQR0rOOdfkwtngIGXKaSs4Ue_QESMtmzWNFu9f-YfoNOc1qY9Xsmk_oEMuJOGUiSP0czlurCs49njeradnGwq-t52PZQXJbrbYB3xni4dQMv7tywovqpvsgL_DlKLbljjaSzzH36aheLfLeYeXoUAKtSyGSs6r2WafT9BBb4cMpy__MfpxffWw-Dq7uf2yXMxvZo5rVWa2k6LTspN92znVMd6LGivWKiYo1OBRMQmWCqvB9tCC1ExTqXstlAKr-DH6vNfdTI8jdG7fsNkkP9q0NdF6838m-JV5is9G7dbIeBX49CKQ4q8JcjGjzw6GwQaIUzZMtlQzypWs6NkbdB2nOvrwlyINI4o0lbrYUy7FnBP0_5qhxOxuad7ckv8B5PyTpw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2570620806</pqid></control><display><type>article</type><title>Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Samhouri, Laith ; Meheissen, Mohamed A. M. ; Ibrahimi, Ahmad K. H. ; Al-Mousa, Abdelatif ; Zeineddin, Momen ; Elkerm, Yasser ; Hassanein, Zeyad M. A. ; Ismail, Abdelsalam Attia ; Elmansy, Hazem ; Al-Hanaqta, Motasem M. ; AL-Azzam, Omar A. ; Elsaid, Amr Abdelaziz ; Kittel, Christopher ; Micke, Oliver ; Stummer, Walter ; Elsayad, Khaled ; Eich, Hans Theodor</creator><creatorcontrib>Samhouri, Laith ; Meheissen, Mohamed A. M. ; Ibrahimi, Ahmad K. H. ; Al-Mousa, Abdelatif ; Zeineddin, Momen ; Elkerm, Yasser ; Hassanein, Zeyad M. A. ; Ismail, Abdelsalam Attia ; Elmansy, Hazem ; Al-Hanaqta, Motasem M. ; AL-Azzam, Omar A. ; Elsaid, Amr Abdelaziz ; Kittel, Christopher ; Micke, Oliver ; Stummer, Walter ; Elsayad, Khaled ; Eich, Hans Theodor</creatorcontrib><description>Background: Central neurocytoma (CN) is a rare tumor accounting for <0.5% of all intracranial tumors. Surgery ± radiotherapy is the mainstay treatment. This international multicentric study aims to evaluate the outcomes of CNs patients after multimodal therapies and identify predictive factors. Patients and methods: We retrospectively identified 33 patients with CN treated between 2005 and 2019. Treatment characteristics and outcomes were assessed. Results: All patients with CN underwent surgical resection. Radiotherapy was delivered in 19 patients. The median radiation dose was 54 Gy (range, 50–60 Gy). The median follow-up time was 56 months. The 5-year OS and 5-year PFS were 90% and 76%, respectively. Patients who received radiotherapy had a significantly longer PFS than patients without RT (p = 0.004) and a trend towards longer OS. In addition, complete response after treatments was associated with longer PFS (p = 0.07). Conclusions: Using RT seems to be associated with longer survival rates with an acceptable toxicity profile.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13174308</identifier><identifier>PMID: 34503124</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Alopecia ; Baldness ; Chemotherapy ; Medical prognosis ; Patients ; Radiation therapy ; Software ; Surgery ; Survival ; Toxicity ; Tumors</subject><ispartof>Cancers, 2021-08, Vol.13 (17), p.4308</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-ad54d95d5f7dc8d23f44d98278241ef44b825ea14a9eafe7e5929159f9488ea83</citedby><cites>FETCH-LOGICAL-c398t-ad54d95d5f7dc8d23f44d98278241ef44b825ea14a9eafe7e5929159f9488ea83</cites><orcidid>0000-0003-2961-9512 ; 0000-0003-2004-2892 ; 0000-0003-0264-1744 ; 0000-0001-9303-7336 ; 0000-0002-2514-4727</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430823/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430823/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Samhouri, Laith</creatorcontrib><creatorcontrib>Meheissen, Mohamed A. M.</creatorcontrib><creatorcontrib>Ibrahimi, Ahmad K. H.</creatorcontrib><creatorcontrib>Al-Mousa, Abdelatif</creatorcontrib><creatorcontrib>Zeineddin, Momen</creatorcontrib><creatorcontrib>Elkerm, Yasser</creatorcontrib><creatorcontrib>Hassanein, Zeyad M. A.</creatorcontrib><creatorcontrib>Ismail, Abdelsalam Attia</creatorcontrib><creatorcontrib>Elmansy, Hazem</creatorcontrib><creatorcontrib>Al-Hanaqta, Motasem M.</creatorcontrib><creatorcontrib>AL-Azzam, Omar A.</creatorcontrib><creatorcontrib>Elsaid, Amr Abdelaziz</creatorcontrib><creatorcontrib>Kittel, Christopher</creatorcontrib><creatorcontrib>Micke, Oliver</creatorcontrib><creatorcontrib>Stummer, Walter</creatorcontrib><creatorcontrib>Elsayad, Khaled</creatorcontrib><creatorcontrib>Eich, Hans Theodor</creatorcontrib><title>Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis</title><title>Cancers</title><description>Background: Central neurocytoma (CN) is a rare tumor accounting for <0.5% of all intracranial tumors. Surgery ± radiotherapy is the mainstay treatment. This international multicentric study aims to evaluate the outcomes of CNs patients after multimodal therapies and identify predictive factors. Patients and methods: We retrospectively identified 33 patients with CN treated between 2005 and 2019. Treatment characteristics and outcomes were assessed. Results: All patients with CN underwent surgical resection. Radiotherapy was delivered in 19 patients. The median radiation dose was 54 Gy (range, 50–60 Gy). The median follow-up time was 56 months. The 5-year OS and 5-year PFS were 90% and 76%, respectively. Patients who received radiotherapy had a significantly longer PFS than patients without RT (p = 0.004) and a trend towards longer OS. In addition, complete response after treatments was associated with longer PFS (p = 0.07). Conclusions: Using RT seems to be associated with longer survival rates with an acceptable toxicity profile.</description><subject>Alopecia</subject><subject>Baldness</subject><subject>Chemotherapy</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>Software</subject><subject>Surgery</subject><subject>Survival</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1PGzEQhq2qqCDg3KslLr0E_Llrc6gURdBGogUheraMd5Y43bVT20uVf1-nQRXFh_GM5plX84HQR0rOOdfkwtngIGXKaSs4Ue_QESMtmzWNFu9f-YfoNOc1qY9Xsmk_oEMuJOGUiSP0czlurCs49njeradnGwq-t52PZQXJbrbYB3xni4dQMv7tywovqpvsgL_DlKLbljjaSzzH36aheLfLeYeXoUAKtSyGSs6r2WafT9BBb4cMpy__MfpxffWw-Dq7uf2yXMxvZo5rVWa2k6LTspN92znVMd6LGivWKiYo1OBRMQmWCqvB9tCC1ExTqXstlAKr-DH6vNfdTI8jdG7fsNkkP9q0NdF6838m-JV5is9G7dbIeBX49CKQ4q8JcjGjzw6GwQaIUzZMtlQzypWs6NkbdB2nOvrwlyINI4o0lbrYUy7FnBP0_5qhxOxuad7ckv8B5PyTpw</recordid><startdate>20210826</startdate><enddate>20210826</enddate><creator>Samhouri, Laith</creator><creator>Meheissen, Mohamed A. M.</creator><creator>Ibrahimi, Ahmad K. H.</creator><creator>Al-Mousa, Abdelatif</creator><creator>Zeineddin, Momen</creator><creator>Elkerm, Yasser</creator><creator>Hassanein, Zeyad M. A.</creator><creator>Ismail, Abdelsalam Attia</creator><creator>Elmansy, Hazem</creator><creator>Al-Hanaqta, Motasem M.</creator><creator>AL-Azzam, Omar A.</creator><creator>Elsaid, Amr Abdelaziz</creator><creator>Kittel, Christopher</creator><creator>Micke, Oliver</creator><creator>Stummer, Walter</creator><creator>Elsayad, Khaled</creator><creator>Eich, Hans Theodor</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2961-9512</orcidid><orcidid>https://orcid.org/0000-0003-2004-2892</orcidid><orcidid>https://orcid.org/0000-0003-0264-1744</orcidid><orcidid>https://orcid.org/0000-0001-9303-7336</orcidid><orcidid>https://orcid.org/0000-0002-2514-4727</orcidid></search><sort><creationdate>20210826</creationdate><title>Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis</title><author>Samhouri, Laith ; Meheissen, Mohamed A. M. ; Ibrahimi, Ahmad K. H. ; Al-Mousa, Abdelatif ; Zeineddin, Momen ; Elkerm, Yasser ; Hassanein, Zeyad M. A. ; Ismail, Abdelsalam Attia ; Elmansy, Hazem ; Al-Hanaqta, Motasem M. ; AL-Azzam, Omar A. ; Elsaid, Amr Abdelaziz ; Kittel, Christopher ; Micke, Oliver ; Stummer, Walter ; Elsayad, Khaled ; Eich, Hans Theodor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-ad54d95d5f7dc8d23f44d98278241ef44b825ea14a9eafe7e5929159f9488ea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alopecia</topic><topic>Baldness</topic><topic>Chemotherapy</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>Software</topic><topic>Surgery</topic><topic>Survival</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Samhouri, Laith</creatorcontrib><creatorcontrib>Meheissen, Mohamed A. M.</creatorcontrib><creatorcontrib>Ibrahimi, Ahmad K. H.</creatorcontrib><creatorcontrib>Al-Mousa, Abdelatif</creatorcontrib><creatorcontrib>Zeineddin, Momen</creatorcontrib><creatorcontrib>Elkerm, Yasser</creatorcontrib><creatorcontrib>Hassanein, Zeyad M. A.</creatorcontrib><creatorcontrib>Ismail, Abdelsalam Attia</creatorcontrib><creatorcontrib>Elmansy, Hazem</creatorcontrib><creatorcontrib>Al-Hanaqta, Motasem M.</creatorcontrib><creatorcontrib>AL-Azzam, Omar A.</creatorcontrib><creatorcontrib>Elsaid, Amr Abdelaziz</creatorcontrib><creatorcontrib>Kittel, Christopher</creatorcontrib><creatorcontrib>Micke, Oliver</creatorcontrib><creatorcontrib>Stummer, Walter</creatorcontrib><creatorcontrib>Elsayad, Khaled</creatorcontrib><creatorcontrib>Eich, Hans Theodor</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samhouri, Laith</au><au>Meheissen, Mohamed A. M.</au><au>Ibrahimi, Ahmad K. H.</au><au>Al-Mousa, Abdelatif</au><au>Zeineddin, Momen</au><au>Elkerm, Yasser</au><au>Hassanein, Zeyad M. A.</au><au>Ismail, Abdelsalam Attia</au><au>Elmansy, Hazem</au><au>Al-Hanaqta, Motasem M.</au><au>AL-Azzam, Omar A.</au><au>Elsaid, Amr Abdelaziz</au><au>Kittel, Christopher</au><au>Micke, Oliver</au><au>Stummer, Walter</au><au>Elsayad, Khaled</au><au>Eich, Hans Theodor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis</atitle><jtitle>Cancers</jtitle><date>2021-08-26</date><risdate>2021</risdate><volume>13</volume><issue>17</issue><spage>4308</spage><pages>4308-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Background: Central neurocytoma (CN) is a rare tumor accounting for <0.5% of all intracranial tumors. Surgery ± radiotherapy is the mainstay treatment. This international multicentric study aims to evaluate the outcomes of CNs patients after multimodal therapies and identify predictive factors. Patients and methods: We retrospectively identified 33 patients with CN treated between 2005 and 2019. Treatment characteristics and outcomes were assessed. Results: All patients with CN underwent surgical resection. Radiotherapy was delivered in 19 patients. The median radiation dose was 54 Gy (range, 50–60 Gy). The median follow-up time was 56 months. The 5-year OS and 5-year PFS were 90% and 76%, respectively. Patients who received radiotherapy had a significantly longer PFS than patients without RT (p = 0.004) and a trend towards longer OS. In addition, complete response after treatments was associated with longer PFS (p = 0.07). Conclusions: Using RT seems to be associated with longer survival rates with an acceptable toxicity profile.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34503124</pmid><doi>10.3390/cancers13174308</doi><orcidid>https://orcid.org/0000-0003-2961-9512</orcidid><orcidid>https://orcid.org/0000-0003-2004-2892</orcidid><orcidid>https://orcid.org/0000-0003-0264-1744</orcidid><orcidid>https://orcid.org/0000-0001-9303-7336</orcidid><orcidid>https://orcid.org/0000-0002-2514-4727</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-08, Vol.13 (17), p.4308 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8430823 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Alopecia Baldness Chemotherapy Medical prognosis Patients Radiation therapy Software Surgery Survival Toxicity Tumors |
| title | Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T02%3A39%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Adjuvant%20Radiotherapy%20in%20Patients%20with%20Central%20Neurocytoma:%20A%20Multicentric%20International%20Analysis&rft.jtitle=Cancers&rft.au=Samhouri,%20Laith&rft.date=2021-08-26&rft.volume=13&rft.issue=17&rft.spage=4308&rft.pages=4308-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13174308&rft_dat=%3Cproquest_pubme%3E2570620806%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2570620806&rft_id=info:pmid/34503124&rfr_iscdi=true |